Pharmacological targeting of adenosine receptor signaling

Maria Peleli a, Bertil B. Fredholm a, Luis Sovervie b, c, d, Mattias Carlström a, *

a Department of Physiology and Pharmacology, Karolinska Institutet, Sweden
b Cellular and Molecular Physiology Laboratory (CMPL), Division of Obstetrics and Gynaecology, School of Medicine, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago 8330024, Chile
c Department of Physiology, Faculty of Pharmacy, Universidad de Sevilla, Seville E-41012, Spain
d University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine and Biomedical Sciences, University of Queensland, Herston, QLD 4029, Queensland, Australia

Abstract

Adenosine receptor signaling plays important roles in normal physiology, but is also known to modulate the development or progression of several different diseases. The design of new, efficient, and safe pharmacological approaches to target the adenosine system may have considerable therapeutic potential, but is also associated with many challenges. This review summarizes the main challenges of adenosine receptor targeted treatment including tolerance, disease stage, cell type-specific effects, caffeine intake, adenosine level assessment and receptor distribution in vivo. Moreover, we discuss several potential ways to overcome these obstacles (i.e., the use of partial agonists, indirect receptor targeting, allosteric enhancers, prodrugs, non-receptor-mediated effects, neoreceptors, conditional knockouts). It is important to address these concerns during development of new and successful therapeutic approaches targeting the adenosine system.

© 2017 Elsevier Ltd. All rights reserved.

1. Introduction

Since adenosine receptor-mediated signaling plays a role in modulating the progression of various pathological disorders, the creation of efficient and safe pharmacological ligands has considerable therapeutic potential, but is fraught with difficulty (Chen et al., 2013). Efforts in medicinal and organic chemistry have been fruitful and numerous adenosine analogues with high affinity and selectivity have been generated (Fredholm et al., 2001, 2011). Therefore, the lack of selective ligands is not the major problem. The biggest challenge to overcome is the widespread expression of adenosine receptors and the redundance of adenosine signaling.

2. Challenges associated with pharmacological targeting of adenosine signaling

2.1. Widespread distribution of adenosine receptors

Adenosine receptors are present on most cells. This means that a given type of adenosine receptor is going to be present not only on the target cell(s) involved in a disease process, but also on cells that are involved in very diverse physiological processes. This problem is accentuated with promiscuous agonists, which activate all receptors, than with antagonists selective to cells with substantial ongoing activation (Chen et al., 2013).

2.2. Tolerance

Tolerance can develop after repeated or chronic ligand exposure desensitizing receptor activation or reducing the signaling response of the targeted receptor over time. This can be due to reduced receptor expression, receptor internalization, or other mechanisms reducing the end effect of a specific dose of ligand. Tolerance has been reported for A1AR agonists and A2AR agonists (Burgueno et al., 2003; de Mendonca et al., 2000; Jacobson et al., 1996), but it seems likely to occur also for A2B and A3 agonists. Use of receptor...
antagonists decreases the risk of tolerance, since this would require that the endogenous agonist occupies enough receptors as to cause desensitization. Indeed, even for A2AR which is very abundant in the basal ganglia, constantly occupied antagonists do not cause tolerance, making such drugs promising as therapeutic agents (Hallén et al., 2000; Pinna et al., 2001).

2.3. Developmental or disease stage

Many times the blockade of a specific adenosine receptor has almost opposite effects depending on the developmental stage of the tested animals. This has already been reported in relation to the role of A1AR or A2BAR in brain injury (Aden et al., 2003; Chen et al., 1999; Cunha, 2005; Turner et al., 2003) and in relation to metabolic abnormalities, contradictory findings related to the A1 and A2B receptors could be attributed to the different developmental stages (Csoka et al., 2014; Figler et al., 2011; Johansson et al., 2007; Peleli et al., 2015; Yang et al., 2015). Moreover, in various disease models both protective and detrimental effects of adenosine receptor activation have been observed depending on the stage of the disorder confirming the high complexity of the adenosine receptor-mediated signaling (Chen et al., 2013). This also has implications in the conclusions one can draw from single adenosine receptor knockout mice on the usefulness of adenosine receptor antagonists.

2.4. Distinct effects on different cell types

The distinct effects of adenosine on different cell types become evident in the case of metabolic disorders. For example, diabetes mellitus involve the participation of many different organs such as pancreas, liver, skeletal muscle, and adipose tissue. Moreover, low-grade inflammation together with oxidative stress has been shown to be important in the progression of metabolic abnormalities. Considering that all the adenosine receptors are expressed on the different metabolic organs and various immune cells it becomes evident that the administration of a molecule that targets a specific adenosine receptor will have many and potentially opposing outcomes. For example, as nicely reviewed by Eisenstein et al. (2015), there are many opposing findings regarding the role of A2BAR in metabolic pathologies since this receptor simultaneously and differently affects acute and chronic inflammation (macrophages), adipogenesis (adipose tissue), insulin release (pancreas) and gluconeogenesis as well as glycogenolysis (liver). Additionally, A2BAR receptors seem essential in developing or maintaining endothelial dysfunction in the fetoplacental vasculature in diseases of pregnancy such as gestational diabetes mellitus or preeclampsia (Salsoso et al., 2015; Sobrevia et al., 2016). However, the A1AR is required for the effect of insulin correcting the gestational diabetes mellitus-enhanced L-arginine transport in this vascular bed (Guzman-Gutierrez et al., 2016).

2.5. Widespread use of caffeine

Although often underestimated, a very large part of the adult population consumes coffee on a daily basis. Two cups of coffee leads to an almost 50% blockade of the A1AR and A2BAR (Fredholm et al., 1999). Therefore, any new drug on the market that inhibits adenosine receptors should be able to exert a larger and more obvious effect compared to the one already existing from the low-cost caffeine. In agreement to this concept, any new clinical trial affecting adenosine receptors must carefully calculate the caffeine intake of the study’s participants and interpret any results with caution.

2.6. Measuring adenosine levels or the number-distribution of adenosine receptors in vivo

The reliable measurement of adenosine and its receptors on a specific tissue in vivo is crucial for understanding its biology and pharmacology. However, adenosine’s concentration varies a lot over time and current methodological approaches destroy some cells locally, potentially leading to higher false positive measurements (Chen et al., 2013). Interestingly, the adenosine plasma concentration in the human umbilical vein at birth is higher in gestational diabetes mellitus compared with normal pregnancies (Westermeyer et al., 2015), and maternal plasma concentration of this nucleoside is elevated at early stages of pregnancy in women that later develop preeclampsia (Escudero and Sobrevia, 2008; Espinoza et al., 2011). Moreover, we are still lacking knowledge of how the different receptors are distributed in patients with various diseases. The latter problem could be potentially solved by taking advantage of the newest in vivo imaging methods already in practice with A2AR ligands in patients with Parkinson’s disease (Mishina et al., 2011; Ramlahansingh et al., 2011). Therefore, the advancement in analytical methods for assessing adenosine and its receptors would be of great aid for the use of adenosine receptor drugs in therapy only when adenosine receptor alterations are observed as an example of personalized medicine.

3. Potential approaches to target adenosine receptor signaling

There are several potential ways to overcome some of the abovementioned obstacles, including:

3.1. Partial agonists

Partial agonists are drugs that bind to and activate a receptor, but they have only partial efficacy compared to the full agonist. In practice this means that a partial agonist acts predominantly as an antagonist when there is substantial endogenous signaling of the targeted receptor (Lambert, 2004). Indeed, many commonly used “agonists” are in fact partial agonists. High expression levels of a receptor are positively correlated to the receptor reserve phenomenon across different tissues (Kenakin, 2009). Receptor reserve, which means that stimulation of only a fraction of the receptors is sufficient to elicit the maximum response in case of a full agonist, is very sensitive to an agonist’s intrinsic efficacy. This implies that a full agonist can exert strong effects even at tissues where there is relatively low expression of a receptor. This simultaneous action of a full agonist on many target tissues could lead potentially to many side effects. However, this is not the case when a partial agonist is administrated and therefore many of the side effects on other tissues are avoided. For example, the adipocytes highly express A1AR and therefore partial A1AR agonists can more selectively target those receptors instead of others (Dhalla et al., 2003).

3.2. Indirect receptor targeting

An alternative approach that could lead to less side effects is to increase the local endogenous adenosine concentration and therefore activate the surrounding adenosine receptors. This approach could provide some degree of tissue specificity, but more studies are warranted in order to establish this hypothesis. Drugs that could be used include adenosine deaminase inhibitors (e.g. deoxycoformycin) and adenosine uptake inhibitors, including dipryridamole and ticagrelor. Both deoxycoformycin and ticagrelor have already been used in clinical trials with T1D or acute coronary